Combination of mangiferin and T0901317 targeting autophagy promotes cholesterol efflux from macrophage foam cell in atherosclerosis

Background: The synthetic liver X receptor ligand (LXR) T0901317 (T0) has been reported to attenuate atherosclerosis (AS) without hyperglyceridemia due to innovative drug combination or nano-sized drug delivery. Given the key roles of mangiferin (MGF) in lipid metabolism and atherogenesis, it is critical to investigate progression of atherosclerotic lesion after combined treatment of MGF and T0.

Methods: Atherosclerotic plaque formation and hepatic lipid accumulation were compared in apoE^-/- mice among T0 and/or MGF treatment. The in vitro functions of MGF and T0 were analyzed by Oil-red O staining, Cholesterol efflux assay, transmission electron microscopy and western blot analyses with or without acetylated low density lipoprotein.

Results: The combination therapy are effective regulators for atherosclerotic plaque formation in apoE^-/- mice, due to upregulation of ABCA1 and ABCG1 induced by LXR activation. Subsequently, we identified Autophagy promoted by MGF and T0 treatment establishes a positive feedback loop that increases Cholesterol efflux, resulted from LXRα activation. Under atherogenic conditions, the Autophagy Inhibitor CQ abolished the enhancement effect on Cholesterol outflow of MGF and T0. Mechanically, MGF and T0 promotes LXRα and mTOR/AMPK signaling cascade in macrophage, and promotes AMPK signaling cascade in hepatocyte, leading to lipid metabolic homeostasis.

Conclusions: Altogether, our findings reveal that MGF and T0 engages in AS therapy without side effects by activating AMPK-dependent Autophagy to promote macrophage Cholesterol efflux, and MGF might serve as a natural compound to assist T0 in AS via targeting Autophagy.

Autophagy; Cholesterol efflux; Macrophage foam cells; Mangiferin; T0901317.